Kidney cancer charity slams NICE rejection of Keytruda/Inlyta
NICE says the combination’s cost-effectiveness estimate is higher than what is considered acceptable for NHS use
Read Moreby Selina McKee | Aug 28, 2020 | News | 0
NICE says the combination’s cost-effectiveness estimate is higher than what is considered acceptable for NHS use
Read Moreby Anna Smith | Jul 30, 2019 | News | 0
The CHMP’s recommendation will now be reviewed by the European Commission for marketing authorisation.
Read Moreby Anna Smith | Jul 22, 2019 | News | 0
The opinion is for the indication of RCC, the most common kind of kidney cancer found in adults.
Read Moreby Anna Smith | May 15, 2019 | News | 0
The decision was based on positive results from the Phase III JAVELIN Renal 101 study.
Read Moreby Anna Smith | Apr 24, 2019 | News | 0
The approval is based on results of the KEYNOTE-426 study, in which Keytruda in combination with Inlyta was found to reduce the risk of death by nearly half compared to Sutent.
Read Moreby Anna Smith | Feb 13, 2019 | News | 0
The US Food and Drug Administration has accepted for priority review a supplemental Biologics License Application for Merck’s Bavencio (avelumab) in combination with Inlyta (axitinib) for patients with advanced renal cell carcinoma (RCC).
Read Moreby Selina McKee | Oct 19, 2018 | News | 0
A pivotal Phase III trial investigating a combination of MSD’s anti-PD-1 therapy Keytruda and Pfizer’s tyrosine kinase inhibitor Inlyta has shown a significant benefit on both overall (OS) and progression-free survival (PFS) in patients with kidney cancer.
Read Moreby Selina McKee | Sep 12, 2018 | News | 0
Merck KGaA and Pfizer say they intend to seek US approval of a combination of Bavencio and Inlyta for kidney cancer on the back of progression-free survival data from a late-stage trial.
Read Moreby Selina McKee | Apr 12, 2018 | News | 0
Pfizer is terminating a late-stage trial assessing Inlyta in patients at risk of kidney cancer recurrence after an interim analysis showed that it was highly unlikely the drug would offer any benefit in this setting.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
